Trexquant Investment’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Trexquant Investment’s Portfolio GTHX Stock Details GTHX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-39,465	Closed	-$214K	–	1854
2022 Q4	$214K	Sell	39,465 -27,828	-41%	-$233K	0.01%	1223
2022 Q3	$840K	Buy	67,293 +49,122	+270%	+$561K	0.03%	593
2022 Q2	$90K	Buy	+18,171	New	+$101K	﹤0.01%	1442
2021 Q1	–	Sell	-17,055	Closed	-$307K	–	1544
2020 Q4	$307K	Sell	17,055 -60,615	-78%	-$906K	0.03%	676
2020 Q3	$897K	Buy	+77,670	New	+$1.28M	0.06%	457
2019 Q4	–	Sell	-9,548	Closed	-$218K	–	1311
2019 Q3	$218K	Buy	+9,548	New	+$301K	0.02%	725
2019 Q1	–	Sell	-10,054	Closed	-$193K	–	1380
2018 Q4	$193K	Sell	10,054 -3,254	-24%	-$122K	0.01%	923
2018 Q3	$696K	Buy	+13,308	New	+$726K	0.05%	449

Other funds holding GTHX

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Trexquant Investment's GTHX Position: Q1 2023 in Review

Trexquant Investment sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q1 2023, closing a stake of 39,465 shares — an estimated $214K sold.

Trexquant Investment first reported a position in GTHX in Q3 2018 and held it in 8 quarters. The position peaked at $897K in Q3 2020. 96 funds tracked by Wall St. Rank hold GTHX as of Q1 2023.

Trexquant Investment reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Trexquant Investment sold 39,465 G1 Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $214K.
Trexquant Investment first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2018 and held it in 8 quarters.
Trexquant Investment's G1 Therapeutics, Inc. Common Stock position peaked at $897K in Q3 2020.
96 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Trexquant Investment's 13F filing for Q1 2023, filed 15 May 2023.